HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gil Fine Selected Research

amuvatinib

2/2013A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors.
7/2012Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gil Fine Research Topics

Disease

3Neoplasms (Cancer)
02/2013 - 12/2003
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/2021
1Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
02/2013
1Hematologic Neoplasms (Hematological Malignancy)
12/2003

Drug/Important Bio-Agent (IBA)

2amuvatinibIBA
02/2013 - 07/2012
1alvocidib (flavopiridol)IBA
10/2021
1Cytarabine (Cytosar-U)FDA LinkGeneric
10/2021
1Mitoxantrone (Novantrone)FDA LinkGeneric
10/2021
1Biomarkers (Surrogate Marker)IBA
10/2021
1Imatinib Mesylate (Gleevec)FDA Link
02/2013
1Sunitinib (Sutent)FDA Link
02/2013
1Tyrosine Kinase InhibitorsIBA
02/2013
1Deoxyglucose (2 Deoxy D glucose)IBA
02/2013
1PowdersIBA
07/2012
1DecitabineFDA Link
12/2003
1MethyltransferasesIBA
12/2003
1Cytotoxins (Cytolysins)IBA
12/2003
1A-Form DNA (A-DNA)IBA
12/2003

Therapy/Procedure

1Therapeutics
02/2013